Daniel Torrent: A New Path for ‘No-Optional’ Patients – TADV vs Standard of Care in CLTI
Daniel Torrent, Vascular Surgeon at Longstreet Clinic, shared a post on LinkedIn about a recent article by Mounika Naidu Boya et al, published in Journal of Vascular Surgery:
“‘No-option’ CLTI doesn’t have to mean ‘no hope.’
The results of this systematic review and meta-analysis on TADV (Transcatheter Arterialization of Deep Veins) aren’t surprising if you’ve been paying attention to this world. It’s still nice to see it pulled together and peer reviewed.
The most striking stat? Survival. Even though the patients undergoing TADV have similar medical issues to those that don’t, there’s a fairly startling difference in mortality. Saving limbs saves lives.
Interpreting Patency: Patency isn’t on the infographic because there isn’t anything to compare to on the Standard of Care (SoC) cohort which comes from a natural history study. However, generally, primary and primary-assisted patency is less than 50% at six months. Despite this, the limb preservation statistics are wonderful. This procedure works differently than a standard revascularization.
Optimizing for Success: I’ve been impressed with how this procedure has been implemented as well. It wasn’t just thrown out into the market. It’s been a thoughtful rollout with mandatory training and program support. Beyond training on the procedure, I’ve had help on training the ultrasound team for pre-operative and post-operative evaluations. CLTI is a process where the full spectrum of care matters.”
Title: Evidence for transcatheter arterialization of deep veins in poor-option chronic limb-threatening ischemia: A systematic review and meta-analysis
Authors: Mounika Naidu Boya,Isabella Ferlini Cieri, Adriana A. Rodriguez Alvarez, Shiv Patel, Peter A. Schneider, Daniel Clair, Mehdi H. Shishehbor, Anahita Dua
Read the Full Article on Journal of Vascular Surgery
Stay updated with Hemostasis Today.
-
Feb 3, 2026, 15:11WFH: Latest News from the WHO Executive Board Session in Geneva
-
Feb 3, 2026, 14:54300 Million People, One Global Community – Rare Disease Day
-
Feb 3, 2026, 14:33Pedro Henrique Las Casas: VTE After BCMA Directed CAR T-Cell Therapy in Multiple Myeloma
-
Feb 3, 2026, 14:26Anuoluwapo Babalola։ What The U.S. Exit from WHO Means for Global Health Leadership
-
Feb 3, 2026, 14:16Michiel Voet: Why Every Military Should Have a Dedicated Blood Unit
-
Feb 3, 2026, 10:53Aurelio Maggio: The Final Chapter of Our Journey Through Thalassemia
-
Feb 3, 2026, 10:40Pedro Perez: Post-Thrombectomy DVT Recovery in 2026 – Closing the Loop on Outcomes
-
Feb 3, 2026, 10:26Ryan Williams: This Article Brings to Light The Complexity of PRP…
-
Feb 3, 2026, 10:05Tiago Lopes: Can AI Predict Immune Reactions of New Drugs? Yes!